SEC Company Response from AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818) (AYTU) — Mar 9, 2016
AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818)
Date: March 9, 2016 · CIK: 0001385818 · Accession: 0001144204-16-086909
AI Filing Summary & Sentiment
File numbers found in text: 333-209874
Show Raw Text
CORRESP
1
filename1.htm
AYTU BIOSCIENCE, INC.
373 Inverness Parkway, Suite 206
Englewood, CO 80112
March 9, 2016
Via EDGAR Delivery
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attention:
Re: Aytu BioScience, Inc.
Registration Statement on Form S-1
Filed March 2, 2016
File No. 333-209874
Ladies and Gentlemen:
Aytu BioScience, Inc., a Delaware corporation
(the “Registrant”), hereby requests that the Securities and Exchange Commission take appropriate action to make the
Registration Statement on Form S-1 (File No. 333-209874) effective as of 4:00 p.m. Eastern Time, Friday, March 11, 2016, or as
soon thereafter as practicable. Please advise our corporate counsel, Alexander M. Donaldson at (919) 781-4000, of any questions.
With respect to the aforementioned registration
statement, the Registrant hereby acknowledges that:
· should the Commission or the staff, acting pursuant to delegated authority,
declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated
authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and
accuracy of the disclosure in the filing; and
· the Registrant will not assert staff comments and the declaration
of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of
the United States.
Very truly yours,
AYTU BIOSCIENCE, INC.
By: /s/ Gregory A. Gould
Gregory A. Gould
Chief Financial Officer